Trelagliptin Succinate – a Potential Once a Week Type 2 Diabetes Drug

Trelagliptin Succinate – a Potential Once a Week Type 2 Diabetes Drug


Cases of Diabetes, particularly type 2 Diabetes have skyrocketed worldwide and in the United States. According to the National Diabetes Information Clearinghouse Diabetes affects 25.8 million people of all ages, or roughly 8.3 percent of the U.S. population. The majority of these cases in the United States, upwards of 90 percent, are of the type 2 origin. With medical analysts predicting a significant climb in cases of type 2 diabetes worldwide over the next several decades, as well as the World Health Organization predicting that there will be 366 million people worldwide affected by diabetes by 2030, innovative and effective treatments are necessary.

Trelagliptin succinate, a unique once weekly medication for patients with type 2 Diabetes is currently at the forefront of pharmaceutical studies. As a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor, trelagliptin succinate is in comprehensive clinical trials which are sponsored by Takeda. All of the available DPP-4 inhibitors for type 2 diabetes are currently offered as a once-daily dose only, so the novel once a week dosing of trelagliptin stands to be a sought after product. This alternative for patients having an option for an easy once a week dose, versus having to remember a daily dose, is enticing to many people.  In addition to the easier administration, trelagliptin has the potential to greatly improve treatment compliance.

Results from Phase III clinical trials commenced in September 2011, with approximately 600 patients with type 2 Diabetes documented as participating in this 52 week, open-label study in Japan.  Estimated to be completed by the second half of 2013, this study is poised to reveal never seen before results, leading to a game changing treatment for patients with type 2 diabetes.  Earlier studies of trelagliptin were completed worldwide in 2008. One of these successful studies compared trelagliptin to a placebo, and also to sitagliptin, which is currently marketed as Januvia.  The doses of trelagliptin were 3.125 mg, 12.5 mg, 50 mg and 100 mg. Exact results have yet to be revealed, however, the study goals appear to be met. These goals, which were a decrease in the HbA(1c) levels of patients at the 12 week mark, have been documented on Takeda’s website. This encouraging news, plus current recruiting for the Phase lll and beyond studies suggest that the prior studies have been successful.

Research and development teams are currently looking at not only the prevention and precursors to type 2 Diabetes, but also at the safest, simplest and best long-term treatment solutions. Due to it’s main advantages of the once-weekly treatment, it’s superior efficacy, and it’s cardiovascular safety test results that are demanded by the FDA and in future by other global regulatory authorities, Trelagliptin Succinate will probably supersede all other ‘gliptins’.

LGM Pharma is one of the few providers of the API Trelagliptin Succinate CAS# 1029877-94-8 in the world, as well as many other reliable and hard to find pharmaceutical products. We are currently offering samples of trelagliptin succinate, and continue to offer complete support to clients throughout the research and development process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service